Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
País como asunto
Tipo del documento
Publication year range
1.
J Appl Toxicol ; 40(11): 1511-1525, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32608137

RESUMEN

The European Union (EU) continuously takes ensuring the safe use of manufactured nanomaterials (MNMs) in consumer products into consideration. The application of a common approach for testing MNMs, including the use of optimized protocols and methods' selection, becomes increasingly important to obtain reliable and comparable results supporting the regulatory framework. In the present study, we tested four representative MNMs, two titanium dioxides (NM100 and NM101) and two silicon dioxides (NM200 and NM203), using the EU FP7-NANoREG approach, starting from suspension and dispersion preparations, through to their characterization and final evaluation of biological effects. MNM dispersions were prepared following a refined NANOGENOTOX protocol and characterized by dynamic light scattering (DLS) in water/bovine serum albumin and in media used for in vitro testing. Potential genotoxic effects were evaluated on human bronchial BEAS-2B cells using micronucleus and Comet assays, and pro-inflammatory effects by cytokines release. Murine macrophages RAW 264.7 were used to detect potential innate immune responses using two functional endpoints (pro-inflammatory cytokines and nitric oxide [NO] production). The interaction of MNMs with RAW 264.7 cells was studied by electron microscopy. No chromosomal damage and slight DNA damage and an oxidative effect, depending on MNMs, were observed in bronchial cells. In murine macrophages, the four MNMs directly induced tumor necrosis factor α or interleukin 6 secretion, although at very low levels; lipopolysaccharide-induced NO production was significantly decreased by the titania and one silica MNM. The application of this approach for the evaluation of MNM biological effects could be useful for both regulators and industries.


Asunto(s)
Política de Salud/legislación & jurisprudencia , Inmunidad Innata/efectos de los fármacos , Nanopartículas del Metal/toxicidad , Nanotecnología/legislación & jurisprudencia , Dióxido de Silicio/toxicidad , Titanio/toxicidad , Pruebas de Toxicidad , Animales , Bronquios/efectos de los fármacos , Bronquios/inmunología , Bronquios/metabolismo , Bronquios/patología , Supervivencia Celular/efectos de los fármacos , Ensayo Cometa , Seguridad de Productos para el Consumidor/legislación & jurisprudencia , Citocinas/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/inmunología , Células Epiteliales/metabolismo , Células Epiteliales/patología , Europa (Continente) , Unión Europea , Regulación Gubernamental , Humanos , Mediadores de Inflamación/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Macrófagos/metabolismo , Macrófagos/patología , Ratones , Micronúcleos con Defecto Cromosómico/inducido químicamente , Pruebas de Micronúcleos , Formulación de Políticas , Células RAW 264.7 , Medición de Riesgo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda